Clostridium difficile is an anaerobic, spore-forming, gram-positive rod that causes a spectrum of antibiotic-associated colitis through the elaboration of two large clostridial toxins and other virulence factors. Since its discovery in 1978 as the agent responsible for pseudomembranous colitis, the organism has continued to evolve into an adaptable, aggressive, hypervirulent strain. Advances in molecular methods and improved animal models have facilitated an understanding of how this organism survives in the environment, adapts to the gastrointestinal tract of animals and humans, and accomplishes its unique pathogenesis. The advances in microbiology have been accompanied by some important clinical observations including increased rates of C. difficile infection, increased virulence, and multiple outbreaks. The major new risk is fluoroquinolone use; there is also an association with proton pump inhibitors and increased recognition of cases in outpatients, pediatric patients, and patients without recent antibiotic use. The combination of more aggressive strains with mobile genomes in a setting of an expanded pool of individuals at risk has refocused attention on and challenged assumptions regarding diagnostic gold standards. Future research is likely to build upon the advancements in phylogenetics to create novel strategies for diagnosis, treatment, and prevention. 
INTRODUCTION
Major contributions to the current knowledge on Clostridium difficile and the disease it causes are the discovery of C. difficile in 1935 (63, 125) , studies of antibiotic-associated enterocolitis in guinea pigs as reported by Hambra et al. (64) in 1943 and later by De Somer and colleagues (37) , the recognition of a cytopathic toxin in the guinea pig model by Green in 1974 (62) , the highly successful clinical experience with oral vancomycin for Staphylococcus aureus enterocolitis as reported by Kahn & Hall in 1966 (71) , and the prospective study of clindamycin colitis by Tedesco et al. reported in 1974 (132) . These observations set the stage to challenge S. aureus as the major pathogen of antibioticassociated colitis using rodent models and clinical observations (18, 19) . These studies converged with reports published in the late 1970s defining the role of C. difficile as the major agent of antibiotic-associated colitis in people and animals (14-17, 19, 54) .
Understanding of the biology of C. difficile colonization as it relates to the human intestinal microbiota has been facilitated by the development of numerous mouse models such as gnotoxenic (germ-free animals) and monoxenic (single-species inoculation) mice (32) . Human fecal flora remains stable and retains bacterial and enzymatic properties when inoculated into the gnotobiotic mice (32) . Such human microbiota-associated (HMA) animals facilitate research on the effects of antimicrobial treatment on the human microbiota and on the protective effects of probiotics (32) . Data from the human microbiome project are likely to extend the observations provided by the HMA mouse model.
In addition to better animal models, molecular advances including whole-genome sequencing have enabled sophisticated phylogenetics studies (5, 66, 121, 127) . This review summarizes to date our knowledge of the biology of C. difficile and the application of that knowledge to the understanding of important facets of C. difficile epidemiology and diagnosis.
Toxinotype: refers to a particular strain of C. difficile based on PCR-restriction fragment analysis of the PaLoc Pathogenicity locus (PaLoc): the section of the C. difficile genome that encodes the genes that regulate toxin production 630. Transmission electron microscopy of these highly purified spores showed that they are composed of an electron-dense outer surface, with the spore coat composed of concentric inner rings (80) . The outer surface of the spore coat contains an exosporium that is smooth in the dormant state but develops numerous filamentous projections that attach to the colonic microvilli during germination (101) . Beyond the exosporium are the spore coat, a clearer cortex region, and then an inner membrane adjacent to the core (80) . Densely packed ribosomes and nucleoproteins are seen in the core (80) .
Highly purified spores permitted the study of their biology and infectivity (80) . Cholate, taurocholate, or glycocholate supplementation of brain heart infusion (BHI) increased germination rates 100-to 1000-fold more than BHI agar plates alone, an observation that has implications for recovery of C. difficile from clinical and environmental samples (80) . Purified spores demonstrated resistance to high temperatures and 70% ethanol but were inactivated by sporicidal agents. Environmental spores infect mice in a dose-dependent manner; the dose required to infect 50% of the mice (ICD50) is ∼7 spores per cm 2 . Genes encoding the spore proteins are dispersed throughout the bacterial genome. Proteases and stress response proteins that putatively protect the spore from oxidative stress during germination are abundant, as are metabolic proteins (80) . Surface-exposed proteins may interact with the extracellular environment and may be important in cellular adhesion (e.g., S-layer protein, SlpA) and germination (80) . These surface-exposed proteins are potential candidates for vaccine targets and novel diagnostic tests. Regulation of sporulation is intimately associated with toxin regulation (137) .
Summary of the Clostridium difficile Strain 630 Genome Sequence
The complete genome sequence of C. difficile strain 630, an epidemic, toxinotype X clinical strain that is virulent and multi-drug resistant, was determined by Sebaihia et al. (121) . This work has provided insight into the genetic factors responsible for organism survival, resistance, and virulence. Some of the important observations are highlighted here. The genome of this organism has a circular chromosome (4,290,252 bp) and a plasmid (7,881 bp) . When compared with the genomes of four other pathogenic Clostridium spp. including C. botulinum and C. tetani, C. difficile shares only 15% of its coding sequences with these species and 50% of the coding sequences are unique to C. difficile (121) . Moreover, 11% of the genome consists of mobile genetic elements such as conjugative transposons capable of integrating into and excising from the host genome (121) .
One of the most important regions of the genome is the pathogenicity locus (PaLoc), which contains five genes, tcdA, tcdB, tcdC, tcdR, and tcdE, responsible for the synthesis and regulation of toxins A (TcdA) and B (TcdB). The genes (cdtA and cdtB) encoding the binary toxin are not found on the PaLoc. Other important genetic loci important in virulence include slpA, a single gene that encodes the S-layer; genes encoding extracellular matrix-binding domains; a collagen protease gene, suggesting that digestion of collagen may occur in vivo; surfaceanchored proteins important for covalent attachment to peptidoglycan; a putative Type IV pilus biosynthesis locus involved in fimbrial biosynthesis; and a cluster of genes involved in extracellular polysaccharide synthesis (121) .
C. difficile has a large number of genes important for survival in the gastrointestinal tract. Several of these coding sequences are dedicated to carbohydrate transport and metabolism. One distinguishing feature is the presence of genes that encode an enzyme p-hydroxyphenylacetate decarboxylase that allows C. difficile to produce and tolerate high concentrations of p-cresol, a bacteriostatic compound. The ability to tolerate this compound may provide a competitive advantage over other intestinal microbes and is responsible for the horse manure odor characteristic of this organism in culture. A 19-gene cluster exists that is involved in ethanolamine degradation, an important constituent of (127) .
The genomes of the hypervirulent strains had a number of deletions compared with strain 630. Some fragments of conjugative transposons (CTn2 and Ctn5) present in the epidemic and hypervirulent strains are not seen in nonepidemic older isolates. The function of the loci is not clear, but they may participate in drug transport (127 
The Pathogenicity Locus
The PaLoc of C. difficile is approximately 19.6 kb in size and is stable and conserved in toxigenic strains (30, 138) . Nontoxigenic strains lack the PaLoc; however, isolates with a defective PaLoc can still cause disease (30, 34) . Five genes are present on the PaLoc, tcdA, tcdB, tcdC -tcdE, and tcdR (Figure 1) . The two toxin genes, tcdA and tcdB, are closely aligned, separated by an intervening sequence (tcdE), and both are transcribed in the same direction (138) . tcdE encodes a holin, a protein whose pore-forming activity allows the release of TcdA and TcdB from the cell (40, 138) . tcdR, found upstream of tcdB, is a major positive regulator of tcdA and tcdB expression (40, 138) . It is responsive to environmental conditions and is increased during stationary phase (40, 138) . tcdC is found downstream of tcdA (Figure 1 ) and is a negative regulator of toxin production, an antisigma factor that destabilizes the TcdR holoenzyme to prevent transcription of the PaLoc (30, 36, 40, 42, 90, 138) . tcdC is expressed during the exponential phase of growth; all other genes are expressed during stationary phase (30, 36, 42, 90, 138 The authors demonstrated that in the presence of sufficient nutrients, such as certain amino acids and GTP, CodY binds to the promoter region of tcdR and represses toxin gene expression (42) . When nutrients in the environment are lacking, toxin gene expression is derepressed (42) . Identification of CodY as a toxin gene regulator may provide a potential target for the development of compounds that are useful in the treatment of C. difficile.
Toxins A and B
TcdA and TcdB are part of the large clostridial toxin family along with Clostridium sordellii lethal toxin and hemorrhagic toxin and Clostridium novyi alpha toxin (36, 138 GTPases, such as Rho, Rac, and Cdc42, in the cell. These small proteins are important in regulating signaling pathways. Glycosylation disrupts these pathways, which results in morphological changes, inhibition of cell division and membrane trafficking, and eventual cell death (36, 138) .
TcdA (308 kDa), an enterotoxin, was originally believed to be the toxin associated with disease, and therefore necessary for virulence, until TcdA−, TcdB+ strains were associated with outbreaks of severe C. difficile infection (52) . TcdB (270 kDa), a cytotoxin, is 100-to 1000-fold more toxic to culture cells than TcdA is. Lyras et al. (88) reported that TcdB, not TcdA, is essential for virulence. In Hamsters infected with toxin B mutants (active toxin A, no toxin B) were less likely to die, and the degree of in vitro cytotoxicity was less than that of wild-type animals (88) . TcdA mutant hamsters died as rapidly as wild-type animals. However, a recent paper by Kuehne et al. (74) refutes the assertion that only toxin B is essential for virulence and re-establishes the observation that both toxins can cause significant disease. In that study, TcdA+, TcdB− isolates were as likely to cause disease as the wild-type strains (74) . The authors hypothesize that differences in the hamster models or in the C. difficile isolates themselves used in the respective studies may account for the differences in their observations (74, 88) .
Both toxins are large single-stranded proteins, and recent X-ray crystallography and small angle X-ray scattering models (SAXS) of TcdB suggest four structural domains (5). These domains include (a) a biologically active N-terminal glucosyltransferase protruding from the core of the protein; (b) a cysteine protease domain; (c) a middle translocation section www.annualreviews.org • Clostridium difficilethat contains a hydrophobic region implicated in toxin delivery; and (d ) a C-terminal receptorbinding domain (5) .
Toxin activity is located in the N-terminal domain, and the first 543 amino acids (aa) are sufficient to elicit full glucosyltransferase activity. This portion is delivered into the cytosol of host cells (68, 119) . Cleavage of the biologically active 543-aa segment occurs between Leu543 and Gly544 in a highly conserved region (115) . Separation occurs by autoproteolysis via the cysteine protease domain (5, 58, 68, 111, 115) and is dependent on host cell inositolphosphate (111) .
The C-terminal domain has short combined repetitive oligopeptides (CROPs) for receptor binding. In animal models of TcdA, carbohydrate structures play a role in toxin binding (5, 116, 138) . These carbohydrates are not present in humans and the glycoprotein gp96 present in the human colon is the receptor for TcdA (116) . The central translocation domain is large, taking up approximately 50% of the total size of holotoxin. There is a hydrophobic stretch on the protein that likely facilitates membrane penetration during translocation (58) .
An understanding of the genetics, structure, and function of each of these domains has led to the following model of toxinogenesis. Toxins enter the host cells by receptor-mediated endocytosis, and they require an acidified endosome for translocation (36, 58, 111, 119, 138) . Acidification induces a conformational change in both toxins, exposing the hydrophobic regions of the translocation domain and leading to subsequent pore formation through which the uncleaved catalytic domain, followed by the cysteine protease domain, translocates through the endosomal membrane into the cytosol (12, 58, 108, 111, 115, 119) . Host cell inositol hexaphosphate induces autocleavage of the toxin by a C. difficile aspartate protease, resulting in biologically active toxin (3, 58, 111, 116) .
Once inside the cell, the toxins target the Ras superfamily of small GTPases (Rho, Rac, and Cdc) (42), modifying them through glycosylation (138) . Glycosylation prevents the structural changes required for active conformation of Rho GTPases, significantly altering the function of these proteins. Cells shrink and become rounded owing to disaggregation of the actin cytoskeleton, eventually dying (119, 138) . Tight junctions between epithelial cells are disrupted. This allows neutrophils to migrate to the intestines, contributing to the inflammatory response, typical of colitis (138) . Biological inactivation of the GTPases results in serious physiological consequences such as inhibition of secretion, transcriptional regulation, and eventual apoptosis (119, 138) . In addition to direct cytotoxic effects, TcdA stimulates release of tumor necrosis factor from activated macrophages as well as cytokine production (138) . These activities cause fluid accumulation and further the inflammatory responses (138).
C. difficile Transferase
C. difficile transferase (CDTa), also known as binary toxin (120, 130) , is encoded by the Cdt locus (CdtLoc). It is found in approximately 6%-12.5% of strains overall. Strains without binary toxin CDT have a conserved 68-bp sequence in place of the CdtLoc (36) . CDT is an ADPribosylating toxin that disrupts the cytoskeleton of the cell, leading to excessive fluid loss, rounding of the cell, and eventual cell death (130) .
CDT is composed of two subunits, CDTa and CDTb. Each component alone is not cytotoxic, both together they cause cytotoxicity in vitro (57, 130) . C. difficile CDT is similar to the binary toxins of other clostridia. The binding site for CDTa in the cell is unknown and its role in pathogenesis is unclear. The fact that the incidence of CDT is higher in some of the epidemic strains suggests that it contributes to the severity of disease. This is evidenced in the work by Geric et al. (57) . The investigators challenged hamsters and inoculated rabbit ileal loops with a TcdA−, TcdB−, CDT+ strain. Marked nonhemorrhagic fluid responses were seen in the rabbit ileal loops. Of the hamsters, 70%-80% became colonized, but showed no signs of disease and no histological changes, and they did not die, compared with animals 17:6 inoculated with TcdA+, TcdB+, CDT− strains that did die (57) .
New findings by Schwan et al. (120) reveal that CDT induces the formation of novel thin, dynamic, microtubules on the surface of epithelial cells, leading to increased adherence of Clostridia in vitro and in vivo. Electron microscopy showed that these protrusions increased the adherence of Clostridia to the epithelial cell surface by approximately fivefold in vitro and fourfold in the mouse large intestine, thereby possibly playing an important role in intestinal colonization (120) .
Other Virulence Factors
Although TcdA and TcdB are the major virulence mechanisms in C. difficile disease, other factors are likely important to disease. C. difficile has a crystalline or paracrystalline S-layer consisting of two proteins on the outer cell surface that coats the entire surface of the vegetative organism (26, 45, 50) . These proteins are integral to adherence and stimulate inflammation and induce antibody responses in the host (26, 45, 50, 116) . Several other C. difficile proteins play a role in attachment to intestinal epithelial cells. Ampicillin and clindamycin stimulate the increased expression of these surface adhesins (36) .
Toxin Variant Strains
Many strains of C. difficile have alterations in the sequences of one or more genes in the PaLoc compared with the sequences of the reference strain VPI 10463. Rupnik et al. (114) developed a polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP) method for toxinotyping C. difficile based on mutations in these genes (114) . Currently there are approximately 28 known toxinotypes (46) . Despite the known role of TcdA in disease, the number of strains lacking TcdA recovered from patients with clinical disease has increased. These strains have TcdB but contain deletions in tcdA, resulting in a truncated form of the toxin. The first A−, B+ strain to be characterized was strain 8864 (toxinotype X) (46, 138) .
It contained a 5.9-kb deletion in the 3 end of tcdA as well as an insertion in tcdE (138) . This strain, which caused tissue damage in rabbit ileal loops, is uncommon in humans (46) . Most TcdA− strains have a 1.8-kb deletion in the 3 CROP region of tcdA, the region responsible for attachment to host cell receptors (see The Pathogenicity Locus, above). The absence of this region also prevents detection by diagnostic assays that use antibodies directed against this area of the toxin. These isolates have been rare causes of disease in the United States but constitute anywhere from 3% of all isolates in the United Kingdom and France to as high as 39% in Japan (46) . The A−, B+ strains described to date belong to toxinotypes VIII, X, XVI, and XVII. The last two also have CDT. Of these, toxinotype VIII seems to be most clinically significant (46) . Severe disease has been reported with these strains (ribotype 017) as has emergence of resistance to both the macrolidelincosamide-streptogramin antibiotics and fluoroquinolones (36, 46) .
In addition to changes in tcdA and tcdB, changes in the other genes of the PaLoc may also alter virulence. In 2003, outbreaks of severe disease in the United States and Canada were caused by a clone of C. difficile designated North American pulsed-field type 1 (NAP1), toxinotype III, ribotype 027, and restriction endonuclease analysis (REA) type B1 (84, 91) . These isolates possessed binary toxin CDT and had an 18-bp deletion in the PaLoc tcdC (91). Quinolone resistance was also an important feature of the clone. Since the original description of the increased and widespread dissemination of this clone, several investigations into the genotypic and phenotypic characteristics of these isolates have been published (118, 126, 127, 139) . In brief, Warny et al. (139) showed that 027 strains produced toxins A and B faster and in greater quantities than control (non-027) strains. In addition, others have shown that the duration of toxin production by 027 strains markedly exceeds that of other clones (118) and that these effects may be related partly to stimulation of germination and toxin production by quinolones (118 (126) . The 18-bp deletion has no effect on toxin production (48, 90) . Rather, there is a correlation between truncation of TcdC, due to the single base-pair deletion at position 117 that results in the formation of a stop codon, and increased toxin production due to derepression of the PaLoc (34, 90, 126, 127) . At least one study failed to demonstrate a consistent correlation between a truncated tcdC alone and increased toxin activity, and the authors caution against using mutations to diagnose patients as having more virulent strains and using this information to determine treatment (95) .
Aside from having altered TcdC, 027 strains have five unique genetic regions not present in historical 027 strains (127) . These genes include mutations that explain not only enhanced toxicity as described above, but motility, survival, increased sporulation (2), and antibiotic resistance (127) . These factors combined may explain the increased severity of disease and mortality associated with these hypervirulent clones.
In addition to emergence of 027 and the A−, B+ 017 clone, strains of two other hypervirulent clones have recently been recognized. PCR ribotypes 053 and 078 (toxinotypes V) cause severe disease in humans. Strain 078 is interesting for a number of reasons. It causes disease in both animals, particularly calves and pigs, and humans. Studies to date have shown a high degree of genetic relatedness in the animal and human strains (38, 60) . Both 027 and 078 strains have increased in frequency in the Netherlands, and clinical illness caused by both strains has similar presentations.
Pathophysiology
As described above, the C. difficile genome enables the organism to express a variety of factors that ensure its survival in the gastrointestinal tract of humans and animals once introduced. Physiological factors that allow colonization include a disturbed or absent microbiota, an important barrier. The HMA model showed that amoxicillin-clavulanic acid treatment of mice did not modify the total numbers of microbes but rather modified the type of microbiota. The authors showed that the BacteroidesPorphyromonas-Prevotella group increased and the Clostridium coccoides-Eubacterium rectale group decreased dramatically (11) . Other have assessed the impact of fluoroquinolone treatment on gut microbiota, which decreases the quantities of enterococci and lactobacilli, Bacteroides spp., and bifidobacteria (118) . In this setting C. difficile endogenous or exogenous spores germinate and vegetative cells multiply. The organism adheres to the mucus layer by means of its multiple adhesins and penetrates the mucus with aid of flagella and proteases. Once it penetrates mucus, the organism adheres to enterocytes and the first phase of pathogenesis, namely colonization, begins. Putative virulence factors that promote colonization include the proteolytic enzyme cysteine protease Cwp84, adhesins such as S-layer proteins, a 66-kDa cell wall protein Cwp66, the GroEL heat shock protein, a 68-kDa fibronectin-binding protein, and the flagella components FliC (flagellin) and FliD (flagellar cap protein) (40) . Genes encoding these proteins are in close proximity on the genome. The second phase of the pathogenic process is toxin production (see The Pathogenicity Locus, above). As described above, alterations in genes that encode all these virulence factors, and not just those encoded in the PaLoc, are important for and explain strain variation in C. difficile disease.
EPIDEMIOLOGY People and Patients as Reservoirs
C. difficile is widely distributed in the environment and is often detected in the colon without pathologic consequences. C. difficile infection (CDI) is restricted to patients with C. difficile replication and toxin production. Rates of colonization and positive stool toxin tests based on multiple reports are summarized in Table 1 (13, 39, 53, 136). C. difficile has been detected in stool from 10% to 40% of most animal species, including cattle, horses, camels, donkeys, snakes, seals, dogs, and cats (82, 141) . It is not clear that it causes disease in most of these animals except in antibiotic-treated horses (21) and rodent models. The organism has also been reported from diverse environmental sources; one report based on 2,580 samples showed positive cultures in 184 samples (7%) including 47% of samples from river water, 21% of soil samples, and 2% of home environment samples (4). Foodborne C. difficile infection. Foodborne CDI is an unproven but biologically plausible mechanism of CDI based on detection of C. difficile in an aggregate total of 90 of 592 (15%) retail meat supplies from diverse animal sources and geographic locations in the United States and Canada (61, 117, 140) ; the dominant strains in these reports are ribotypes 027 and 078.
Risks for C. difficile Infection
Major risks for CDI are antibiotic exposure, advanced age, and exposure to acute or chronic care facilities. Antibiotic treatment is always the leading risk for CDI in people and animals. The initial studies focused on clindamycin (132), which was highest in incidence, and cephalosporins, which were highest in prevalence. In a review of 503 cases in Sweden from 1980 to 1982, the relative risk for these agents compared with other antibiotics was 10 to 70 times higher (6) . The fluoroquinolones emerged as major inducing agents and were implicated in several outbreaks that could be controlled only by restraining or prohibiting use of the entire class (55, 69) . The prominent role of this class since 2000 presumably reflects high use rates combined with the emergence of resistance by ribotype 027 (29, 55, 91) .
Advanced age is a risk, with most reports showing sharp increases in incidence in persons over 65 years and a direct correlation with age above that threshold (6, 102) . A possible contributing factor is immunosenescence, based on reports showing humoral response to toxins A and/or B determines clinical expression (77) and protection afforded by monoclonal antibodies to toxins A and B (86) . It is unclear that defective cell-mediated immunity is an important risk factor.
Another important risk is contact with the healthcare system, which is heavily contaminated by C. difficile, especially case-associated areas (72) . The potential sources of C. difficile acquisition include surface contamination, hospital personnel, patient cases and asymptomatic carriers, and hospital air (22, 31, 44, 52, 72) . This risk is well verified by reports of C. difficile acquisition and CDI in hospitals and chronic care facilities. A prospective study of 428 admissions to Harborview Hospital in Seattle showed 6 (1.5%) patients were colonized on admission from home and 83 (21%) patients became colonized during their hospital stay (92) .
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Risks associated with C. difficile acquisition and infection include age over 65 years, ICU (intensive care unit) admission, antibiotic treatment, length of hospital stay, gastrointestinal procedures, and hospitalization in case-associated areas (10) .
There is increasing evidence that proton pump inhibitors also promote CDI (41) . A systematic review of the literature from 1988 to 2005, based on 12 relevant publications and 2,948 patients with CDI, showed a relative risk of 1.94 (95% CI 1.4-2.8) for proton pump inhibitors (81, 83) .
Changing Epidemiology
Since 2000, there has been a dramatic increase in rates and severity of CDI noted in North America and much of Europe. The first reports were from Sherbrooke in Quebec, Canada, in 2003 showing a fourfold increase in CDI rates, from 35.6 to 156.3/100,000. Subsequent reports indicated this experience affected multiple hospitals in Quebec and included reviews showing the following: an attributable mortality of 6.9%, fluoroquinolones as the dominant inducing agents, 10-fold-higher rates in persons over 65 years, and the "hypervirulent" ribotype 027 as the cause of the epidemic (84, 85, 103) . In the United States an analysis by ICD-9 discharge data showed that the CDI rate doubled, the case mortality increased 80%, and the rate of colectomies for CDI tripled in 2003 compared with 1993 (47, 110, 113, 143) . In addition, the U.S. experience suggested increases in selected patient populations including pediatric patients, persons without recent antibiotic exposure, community-acquired cases, and severe cases associated with pregnancy. European data also showed increased CDI rates and multiple hospital-associated outbreaks (52) .
Emergence of Ribotype 027
The increasing incidence and severity of CDI in North America and much of Europe has been attributed to the emergence of ribotype 027. This strain accounted for only 14 of over 6,000 (<0.02%) typed strains collected from U.S. cases from 1984 to 1993, but was implicated in 96 of 187 (51%) of strains tested in eight U.S. outbreaks from 2000 to 2003 (91, 100) . This strain has been associated with large outbreaks of severe CDI in hospitals in the United States, Canada, and Europe (75, 84, 96, 100) . The factor thought to contribute to incidence is the strain's resistance to fluoroquinolones, and enhanced virulence may reflect increased toxin production in vitro (139) .
In 2008, the European Center for Disease Control established a surveillance system to define CDI incidence and implicated strains in 34 European countries. This showed a mean incidence of 5.5 cases per 10,000 patient days, and ribotype 027 accounted for just 5% of all cases (52) . Unfortunately, there is no natural surveillance system in the United States, but a large clinical trial of a new therapeutic agent in [2005] [2006] [2007] showed that ribotype 027 accounted for 36% of U.S. strains and 8% of European strains (56) .
The data reviewed provide strong support for the role of ribotype 027 in some devastating outbreaks, the important new role of fluoroquinolones for driving incidence, and the critical role of fluoroquinolone restriction in controlling some outbreaks (69, 75) . However, this conclusion may be overly simplified because ribotype 027 accounted for only 5% of 89 typed strains in the 2008 European surveillance study (20) ; a case control study found "no evidence to support assertions that ribotype 027 is more virulent than other PCR ribotypes" (93) . Some institutions report that beta-lactams are still much more important inducing agents than fluoroquinolones (20) and that ribotype 078 has played an important part in some outbreaks (75) .
DIAGNOSIS
Guidelines for diagnosis and treatment of C. difficile disease have been developed by the Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America (SHEA/IDSA) in the United States 17:6 (31, 33) . Both groups recommend that testing be performed only on diarrheal (unformed) stool except in rare instances (31, 33) . Asymptomatic patients should not be tested even for test of cure. Table 2 lists the variety of test methods available for the diagnosis of CDI and a summary of their performances based on published studies. Cell culture cytotoxicity neutralization assays (CCCNAs) are performed by inoculating a stool filtrate onto a monolayer of a particular cell line (e.g., human foreskins fibroblasts) and then observing for toxin-induced cytopathic effect (CPE). Once CPE is observed, neutralization with an antiserum, either C. sordellii antitoxin or C. difficile antitoxin, is performed. For many years, CCCNAs were considered the diagnostic gold standard. However, their performance has recently been re-evaluated in comparisons with toxigenic culture and nucleic acid amplification tests (NAATs) (9, 49, 105, 128) ( Table 2 ). In general, CCCNAs are too insensitive (<90%) to be considered acceptable reference methods (31) .
Enzyme immunoassays (EIAs), the method most frequently used in U.S. laboratories, use polyclonal or monoclonal antibodies targeting TcdA alone or both TcdA and TcdB. Because of the emergence of virulent TcdA−, TcdB+ isolates, clinical laboratories should use a test that detects both toxins. About two dozen solid-phase, well-type, and rapid membrane assays are available. Several recent comprehensive reviews evaluating the performance of these assays have been published (33, 49, 107) . Planche et al. (107) performed a comprehensive review of 28 studies assessing six Toxin A/B assays commonly used in the United Kingdom. The authors noted significant heterogeneity among the assays, but the diagnostic odds ratio implied no difference in performance among them. Most of the assays had higher specificities than sensitivities, but none of the assays met the criteria for an acceptable test, defined as having a sensitivity of 90% and a false-positive rate of ≤3% (107). Eastwood et al. (49) evaluated six EIAs and three lateral flow assays on the same set of 600 diarrheal samples. Sensitivities ranged from 60% to 81% and specificities from 91% to 99.4% compared with toxigenic culture (49). None of the assays met the criteria as defined by Planche et al. (49) .
Because EIAs lack sensitivity, it has become common practice to perform "stools for www.annualreviews.org • Clostridium difficile17:6 C. difficile x 3." However, recent reports demonstrate the lack of utility of repeat testing regardless of the method used (1, 24, 27, 87, 97, 106) . Given the poor sensitivity and positive predictive value in low-prevalence populations, both practice guidelines consider EIAs suboptimal for the diagnosis of C. difficile infections (31, 33) .
Glutamate dehydrogenase (GDH) is a metabolic enzyme expressed at high levels by all strains of C. difficile. GDH is present in both toxigenic and nontoxigenic strains, so a positive GDH test must be combined with an assay that also detects toxin. The C. DIFF CHEK TM -60 solid-phase microtiter plate GDH assay (TechLab, Blacksburg, Virginia) demonstrated high negative predictive values (98.5% to 99.7%) in several studies (51, 124, 135, 142) . Therefore, many laboratories have adopted a two-step algorithm in which the GDH is performed first, and if negative, no further testing is required. If the GDH test is positive, a toxin test should follow. If the GDH is positive but the toxin test is negative, either the patient is colonized with nontoxigenic C. difficile or (depending upon the assay) the toxin test is falsely negative. If both the GDH and the toxin test are positive, then the symptomatic patient likely has CDI. Although some investigators have recently noted suboptimal performance of the GDH assay compared with culture and/or molecular methods (76, 99, 133) , a recent meta-analysis reports that GDH has a greater than 90% sensitivity with a negligible false-positive rate when compared with culture (123) . This two-step method is the approach that is currently recommended by both ESCMID and SHEA/IDSA (31, 33) .
A newer immunochromatogenic membrane version of the test combines both GDH and toxin testing into a single device (C. DIFF Quik Chek Complete TM , TechLab) and takes about 30 min to perform. In two published studies when this device was compared to toxigenic culture, the sensitivity of the GDH component was 100% (109, 131) . However, the toxin component performed poorly; its sensitivity ranging from 61% to 78% (109, 131) . Given the insensitivity of the toxin component of the assay, some laboratories are using the device in an expanded three-step approach, testing the GDH-positive, toxin-negative samples with another method such as a NAAT.
The increase in the incidence of C. difficile infections, the emergence of hypervirulent strains causing more severe disease, and more recently, the need for a better method against which to assess evolving technologies, such as NAATs, have compelled laboratories to revisit anaerobic toxigenic culture. Toxigenic culture requires inoculating stool specimens to selective anaerobic media that contain substances inhibitory to normal stool microbiota while promoting the germination and growth of C. difficile. Both toxigenic and nontoxigenic isolates are recovered, so isolates must be tested for toxin production by EIA, CCCNA, or NAAT. Toxigenic culture performed after negative direct toxin testing by EIA or CCNA increases the yield of positives by 15% to 23% (25, 112) .
Although culture methods have not been standardized, there are some important caveats with respect to its performance. Spore enrichment significantly enhances recovery and is useful when culturing is done for epidemiological purposes. There are two ways to enrich for spores: heat shock and treatment of the specimen with ethanol. The methods are detailed in References 28, 65, 78, and 89.
A variety of media exist for culturing C. difficile. The original cycloserine, cefoxitin, fructose agar (CCFA), as described by George et al. (53) contained an egg yolk fructose agar base with 500 μg ml −1 of cycloserine and 16 μg ml −1 of cefoxitin. CCFA takes advantage of the ability of C. difficile to ferment fructose. CCFA variants with reduced concentrations of the antimicrobial agents are less sensitive than the formulation by George et al. (94, 104) . Additives such as horse blood, taurocholate, and lysozyme improve recovery by enhancing vegetation (23; K. Carroll, personal observations). A recent study demonstrated improved recovery with CCF broth supplemented with 0.1% taurocholate compared with plating on solid agar (7). Whichever method is chosen, it is important to use prereduced media, as the failure to do so can affect the sensitivity of the culture method (104) . Despite its sensitivity, toxigenic culture is not practical for use in most clinical laboratories. However, it is particularly useful in the setting of an outbreak, when evaluating a new test method, for surveillance of antimicrobial resistance, and for management of patients with recurrent/refractory disease.
Nucleic Acid Amplification Methods
In the United States there are currently four FDA-cleared NAATs available for diagnosis of CDI ( Table 2) : (a) the BD-GeneOhm TM Cdiff assay (BD, Franklin Lakes, New Jersey), (b) the Prodesse ProGastro TM Cd assay (Gen-Probe, Inc. San Diego, California), (c) the Cepheid GeneXpert R C difficile (Cepheid, Sunnyvale, California), and (d ) the illumigene TM C. difficile assay (Meridian Diagnostics, Inc., Cincinnati, Ohio). The first three assays target conserved regions of tcdB, and the last uses loop-mediated isothermal amplification to detect the PaLoc at a conserved region of tcdA that is present even in TcdA−, TcdB+ strains. The assays vary considerably in terms of ease of use, instrumentation, and cost. The performance characteristics of these assays are well published in the literature and are highlighted in Table 2 . In general, they are superior to all methods except toxigenic culture. To date, there is no published study that compares them all.
An important observation came from the analysis of the data from the GeneXpert clinical trials. The authors noted that the performance of all the assays evaluated appeared to be affected by the ribotype of the strain causing the infection. Compared with toxigenic culture, the GDH assay and qPCR assay had comparable sensitivity for detection of ribotype 027 (91%) (133) . However, for non-027 infections, the overall sensitivity for the GDH assay was 70% compared with 92% for the GeneXpert assay (133) . These results were statistically significant (133) . Likewise, the performance of two Toxin A/B EIAs revealed extensive variability, with sensitivities as low as 16% for some ribotypes (133) . Although these observations can certainly explain the broad variability in test performance, especially for the EIA methods, it would be useful to see additional data from other sites and other platforms with respect to such observations. NAAT testing is rapidly replacing other methods in clinical microbiology laboratories, particularly in laboratories that already have the required instrumentation for testing. These new technologies have yet to be endorsed by professional society guidelines (31, 33) . There are practical and theoretical concerns that, if clarified, could reassure healthcare practitioners regarding their use. One of these concerns is whether genetic drift of tcdB or other gene targets in regions of primer/probe binding is likely to suddenly affect assay performance. As discussed above, there is a great deal of heterogeneity in the genome of various C. difficile www.annualreviews.org • Clostridium difficilestrains. However, the full and partial genome sequencing of several strains of C. difficile has elucidated regions that are conserved, including regions of genes on the PaLoc that have been targeted for these assays. At least one study showed performance variability based on ribotype (133) . Information about the impact of NAATs on C. difficile transmission and their cost-effectiveness is also needed.
Given the costs of NAATs, some laboratories have explored using them on a limited basis in three-step algorithms as outlined in Figure 2 . The algorithm begins with the C. DIFF Quik CHEK Complete TM test, and NAAT testing is performed only on GDH-positive, EIA-negative specimens. Several studies have demonstrated the costeffectiveness of such an approach (43, 79, 122) .
SUMMARY POINTS
1. The complete genome of a clinical strain of C. difficile and partial genomes of toxin variant strains have been sequenced.
2.
C. difficile causes disease by elaborating one or both large clostridial toxins encoded on a PaLoc with three additional genes that regulate toxin production.
3. Both toxins are large single-stranded proteins, and recent X-ray crystallography and small angle X-ray scattering models of TcdB suggest four structural domains are necessary for toxin entry and cytotoxicity.
4. Binary toxin, which is not encoded on the PaLoc, may contribute to disease severity by its cytotoxic activity and by induction of novel thin, dynamic microtubules on the surface of epithelial cells, leading to increased adherence of Clostridia.
5. Mutations in the PaLoc have resulted in the evolution of four clades of C. difficile inclusive of hypervirulent toxinotypes responsible for aggressive disease.
6. Risk factors such as quinolone antibiotics, proton pump inhibitors, and advanced age, in combination with more pathogenic strains, have created the "perfect storm" for recent epidemics.
7. The recognition of toxin variant strains in domestic animals and food sources may explain the onset of community disease. This needs further study.
8. Increased incidence and severity of disease has refocused attention on the inadequacy of EIAs and CCCNAs and has sparked development of diagnostic molecular assays. 
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